25 XP   0   0   10

Kalbe Farma Tbk PT
Buy, Hold or Sell?

Let's analyse Kalbe together

PenkeI guess you are interested in Kalbe Farma Tbk PT. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Kalbe Farma Tbk PT. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Kalbe Farma Tbk PT

I send you an email if I find something interesting about Kalbe Farma Tbk PT.

Quick analysis of Kalbe (30 sec.)










What can you expect buying and holding a share of Kalbe? (30 sec.)

How much money do you get?

How much money do you get?
Rp0.02
When do you have the money?
1 year
How often do you get paid?
80.0%

What is your share worth?

Current worth
Rp446.98
Expected worth in 1 year
Rp473.03
How sure are you?
87.5%

+ What do you gain per year?

Total Gains per Share
Rp179.30
Return On Investment
12.3%

For what price can you sell your share?

Current Price per Share
Rp1,455.00
Expected price per share
Rp1,405 - Rp1,555
How sure are you?
50%

1. Valuation of Kalbe (5 min.)




Live pricePrice per Share (EOD)

Rp1,455.00

Intrinsic Value Per Share

Rp135.04 - Rp612.87

Total Value Per Share

Rp582.02 - Rp1,059.86

2. Growth of Kalbe (5 min.)




Is Kalbe growing?

Current yearPrevious yearGrowGrow %
How rich?$2b$2b$58.7m2.9%

How much money is Kalbe making?

Current yearPrevious yearGrowGrow %
Making money$74m$84.5m-$10.4m-14.2%
Net Profit Margin9.7%11.9%--

How much money comes from the company's main activities?

3. Financial Health of Kalbe (5 min.)




What can you expect buying and holding a share of Kalbe? (5 min.)

Welcome investor! Kalbe's management wants to use your money to grow the business. In return you get a share of Kalbe.

What can you expect buying and holding a share of Kalbe?

First you should know what it really means to hold a share of Kalbe. And how you can make/lose money.

Speculation

The Price per Share of Kalbe is Rp1,455. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Kalbe.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Kalbe, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is Rp446.98. Based on the TTM, the Book Value Change Per Share is Rp6.51 per quarter. Based on the YOY, the Book Value Change Per Share is Rp6.19 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is Rp38.31 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Kalbe.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 Rp% of Price per ShareRp% of Price per ShareRp% of Price per ShareRp% of Price per ShareRp% of Price per Share
Usd Eps0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Book Value Change Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.010.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Price Per Share0.18-0.20-0.17-0.16-0.15-
Price to Earnings Ratio37.87-36.26-23.45-27.47-29.22-
Price-to-Total Gains Ratio34.08-62.56-2.17-34.42-44.09-
Price to Book Ratio3.93-4.49-3.92-4.18-5.15-
Price-to-Total Gains Ratio34.08-62.56-2.17-34.42-44.09-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.1455
Number of shares6872
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (6872 shares)30.8020.55
Gains per Year (6872 shares)123.2182.20
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
110518113631972
22113623612737154
33165435919056236
44217248225475318
55278960531794400
6632107728381112482
7737125851444131564
8843143974508150646
99481611097571168728
1010531791220635187810

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%40.00.00.0100.0%79.00.00.0100.0%
Book Value Change Per Share3.01.00.075.0%8.04.00.066.7%14.06.00.070.0%29.011.00.072.5%64.015.00.081.0%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%32.00.08.080.0%49.00.030.062.0%
Total Gains per Share4.00.00.0100.0%10.02.00.083.3%18.02.00.090.0%35.05.00.087.5%70.09.00.088.6%

Fundamentals of Kalbe

About Kalbe Farma Tbk PT

PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through four divisions: Prescription Pharmaceuticals; Consumer Health; Nutritionals and Distribution; and Logistic. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biopharma; animal health; international business; and E-health products. It operates Mitrasana Clinics, a health care service. In addition, the company provides health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as offers advertising services. PT Kalbe Farma Tbk. was incorporated in 1966 and is headquartered in Jakarta, Indonesia.

Fundamental data was last updated by Penke on 2024-03-10 12:22:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Kalbe Farma Tbk PT.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Kalbe earns for each Rp1 of revenue.

  • Above 10% is considered healthy but always compare Kalbe to the Drug Manufacturers - General industry mean.
  • A Net Profit Margin of 7.3% means that Rp0.07 for each Rp1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Kalbe Farma Tbk PT:

  • The MRQ is 7.3%. The company is making a profit. +1
  • The TTM is 9.7%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ7.3%TTM9.7%-2.5%
TTM9.7%YOY11.9%-2.2%
TTM9.7%5Y11.3%-1.6%
5Y11.3%10Y11.5%-0.2%
1.1.2. Return on Assets

Shows how efficient Kalbe is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Kalbe to the Drug Manufacturers - General industry mean.
  • 2.0% Return on Assets means that Kalbe generated Rp0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Kalbe Farma Tbk PT:

  • The MRQ is 2.0%. Using its assets, the company is less efficient in making profit.
  • The TTM is 2.7%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ2.0%TTM2.7%-0.7%
TTM2.7%YOY3.3%-0.6%
TTM2.7%5Y3.1%-0.4%
5Y3.1%10Y3.5%-0.4%
1.1.3. Return on Equity

Shows how efficient Kalbe is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Kalbe to the Drug Manufacturers - General industry mean.
  • 2.6% Return on Equity means Kalbe generated Rp0.03 for each Rp1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Kalbe Farma Tbk PT:

  • The MRQ is 2.6%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 3.6%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ2.6%TTM3.6%-1.0%
TTM3.6%YOY4.3%-0.7%
TTM3.6%5Y4.1%-0.5%
5Y4.1%10Y4.6%-0.5%

1.2. Operating Efficiency of Kalbe Farma Tbk PT.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Kalbe is operating .

  • Measures how much profit Kalbe makes for each Rp1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Kalbe to the Drug Manufacturers - General industry mean.
  • An Operating Margin of 0.0% means the company generated Rp0.00  for each Rp1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Kalbe Farma Tbk PT:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM10.2%-10.2%
TTM10.2%YOY11.3%-1.1%
TTM10.2%5Y13.9%-3.7%
5Y13.9%10Y7.3%+6.6%
1.2.2. Operating Ratio

Measures how efficient Kalbe is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • An Operation Ratio of 1.55 means that the operating costs are Rp1.55 for each Rp1 in net sales.

Let's take a look of the Operating Ratio trends of Kalbe Farma Tbk PT:

  • The MRQ is 1.545. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.496. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.545TTM1.496+0.049
TTM1.496YOY1.440+0.056
TTM1.4965Y1.433+0.063
5Y1.43310Y0.991+0.441

1.3. Liquidity of Kalbe Farma Tbk PT.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Kalbe is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A Current Ratio of 3.90 means the company has Rp3.90 in assets for each Rp1 in short-term debts.

Let's take a look of the Current Ratio trends of Kalbe Farma Tbk PT:

  • The MRQ is 3.905. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.708. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.905TTM3.708+0.197
TTM3.708YOY4.125-0.418
TTM3.7085Y4.010-0.302
5Y4.01010Y2.111+1.899
1.3.2. Quick Ratio

Measures if Kalbe is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Kalbe to the Drug Manufacturers - General industry mean.
  • A Quick Ratio of 1.94 means the company can pay off Rp1.94 for each Rp1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Kalbe Farma Tbk PT:

  • The MRQ is 1.941. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.899. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.941TTM1.899+0.042
TTM1.899YOY2.498-0.598
TTM1.8995Y2.276-0.377
5Y2.27610Y1.687+0.589

1.4. Solvency of Kalbe Farma Tbk PT.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Kalbe assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Kalbe to Drug Manufacturers - General industry mean.
  • A Debt to Asset Ratio of 0.24 means that Kalbe assets are financed with 23.9% credit (debt) and the remaining percentage (100% - 23.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Kalbe Farma Tbk PT:

  • The MRQ is 0.239. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.252. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.239TTM0.252-0.012
TTM0.252YOY0.230+0.022
TTM0.2525Y0.221+0.031
5Y0.22110Y0.214+0.007
1.4.2. Debt to Equity Ratio

Measures if Kalbe is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Kalbe to the Drug Manufacturers - General industry mean.
  • A Debt to Equity ratio of 31.5% means that company has Rp0.31 debt for each Rp1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Kalbe Farma Tbk PT:

  • The MRQ is 0.315. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.337. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.315TTM0.337-0.022
TTM0.337YOY0.305+0.031
TTM0.3375Y0.290+0.046
5Y0.29010Y0.282+0.008

2. Market Valuation of Kalbe Farma Tbk PT

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every Rp1 in earnings Kalbe generates.

  • Above 15 is considered overpriced but always compare Kalbe to the Drug Manufacturers - General industry mean.
  • A PE ratio of 37.87 means the investor is paying Rp37.87 for every Rp1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Kalbe Farma Tbk PT:

  • The EOD is 31.395. Based on the earnings, the company is overpriced. -1
  • The MRQ is 37.868. Based on the earnings, the company is overpriced. -1
  • The TTM is 36.261. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD31.395MRQ37.868-6.473
MRQ37.868TTM36.261+1.607
TTM36.261YOY23.446+12.815
TTM36.2615Y27.475+8.786
5Y27.47510Y29.218-1.744
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Kalbe Farma Tbk PT:

  • The EOD is 25.615. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 30.897. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is 1,019.852. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD25.615MRQ30.897-5.281
MRQ30.897TTM1,019.852-988.955
TTM1,019.852YOY-204.212+1,224.065
TTM1,019.8525Y256.338+763.514
5Y256.33810Y153.195+103.143
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Kalbe is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A PB ratio of 3.93 means the investor is paying Rp3.93 for each Rp1 in book value.

Let's take a look of the Price to Book Ratio trends of Kalbe Farma Tbk PT:

  • The EOD is 3.255. Based on the equity, the company is fair priced.
  • The MRQ is 3.926. Based on the equity, the company is fair priced.
  • The TTM is 4.491. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD3.255MRQ3.926-0.671
MRQ3.926TTM4.491-0.565
TTM4.491YOY3.922+0.570
TTM4.4915Y4.177+0.315
5Y4.17710Y5.153-0.976
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Kalbe Farma Tbk PT compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--12.2416.512+88%6.194+98%6.807+80%6.894+78%
Book Value Per Share--446.984445.191+0%428.442+4%391.262+14%319.868+40%
Current Ratio--3.9053.708+5%4.125-5%4.010-3%2.111+85%
Debt To Asset Ratio--0.2390.252-5%0.230+4%0.221+8%0.214+12%
Debt To Equity Ratio--0.3150.337-7%0.305+3%0.290+8%0.282+11%
Dividend Per Share--39.25138.313+2%25.303+55%23.097+70%17.482+125%
Eps--11.58613.813-16%17.930-35%15.075-23%13.549-14%
Free Cash Flow Per Share--14.2016.256+127%1.571+804%7.742+83%10.147+40%
Free Cash Flow To Equity Per Share---29.861-18.859-37%-20.494-31%-5.298-82%3.004-1094%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--612.873--------
Intrinsic Value_10Y_min--135.035--------
Intrinsic Value_1Y_max--43.663--------
Intrinsic Value_1Y_min--28.540--------
Intrinsic Value_3Y_max--144.719--------
Intrinsic Value_3Y_min--73.260--------
Intrinsic Value_5Y_max--262.085--------
Intrinsic Value_5Y_min--103.947--------
Market Cap67301897441280.000-21%81178650674550.00092453463268237.500-12%78361267603162.500+4%76080053849160.000+7%71990658383814.000+13%
Net Profit Margin--0.0730.097-25%0.119-39%0.113-36%0.115-37%
Operating Margin---0.102-100%0.113-100%0.139-100%0.073-100%
Operating Ratio--1.5451.496+3%1.440+7%1.433+8%0.991+56%
Pb Ratio3.255-21%3.9264.491-13%3.922+0%4.177-6%5.153-24%
Pe Ratio31.395-21%37.86836.261+4%23.446+62%27.475+38%29.218+30%
Price Per Share1455.000-21%1755.0001998.750-12%1678.750+5%1629.750+8%1548.375+13%
Price To Free Cash Flow Ratio25.615-21%30.8971019.852-97%-204.212+761%256.338-88%153.195-80%
Price To Total Gains Ratio28.257-21%34.08362.560-46%2.167+1473%34.421-1%44.091-23%
Quick Ratio--1.9411.899+2%2.498-22%2.276-15%1.687+15%
Return On Assets--0.0200.027-27%0.033-39%0.031-37%0.035-44%
Return On Equity--0.0260.036-28%0.043-40%0.041-36%0.046-44%
Total Gains Per Share--51.49244.824+15%31.497+63%29.904+72%24.375+111%
Usd Book Value--2067555472.4292059261794.175+0%2000546734.175+3%1826950080.576+13%1488640935.217+39%
Usd Book Value Change Per Share--0.0010.001+88%0.001+98%0.001+80%0.001+78%
Usd Book Value Per Share--0.0450.045+0%0.043+4%0.039+14%0.032+40%
Usd Dividend Per Share--0.0040.004+2%0.003+55%0.002+70%0.002+125%
Usd Eps--0.0010.001-16%0.002-35%0.002-23%0.001-14%
Usd Free Cash Flow--65685571.31128936015.982+127%7359954.070+792%36210415.393+81%47156458.136+39%
Usd Free Cash Flow Per Share--0.0010.001+127%0.000+804%0.001+83%0.001+40%
Usd Free Cash Flow To Equity Per Share---0.003-0.002-37%-0.002-31%-0.001-82%0.000-1094%
Usd Market Cap6730189744.128-21%8117865067.4559245346326.824-12%7836126760.316+4%7608005384.916+7%7199065838.381+13%
Usd Price Per Share0.146-21%0.1760.200-12%0.168+5%0.163+8%0.155+13%
Usd Profit--53592842.28974040534.697-28%84535022.292-37%72617397.499-26%64133900.557-16%
Usd Revenue--738207705.513757818460.704-3%708606751.542+4%644489199.247+15%560099253.804+32%
Usd Total Gains Per Share--0.0050.004+15%0.003+63%0.003+72%0.002+111%
 EOD+4 -4MRQTTM+19 -16YOY+17 -185Y+18 -1710Y+20 -15

3.2. Fundamental Score

Let's check the fundamental score of Kalbe Farma Tbk PT based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1531.395
Price to Book Ratio (EOD)Between0-13.255
Net Profit Margin (MRQ)Greater than00.073
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.941
Current Ratio (MRQ)Greater than13.905
Debt to Asset Ratio (MRQ)Less than10.239
Debt to Equity Ratio (MRQ)Less than10.315
Return on Equity (MRQ)Greater than0.150.026
Return on Assets (MRQ)Greater than0.050.020
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Kalbe Farma Tbk PT based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.551
Ma 20Greater thanMa 501,466.000
Ma 50Greater thanMa 1001,501.100
Ma 100Greater thanMa 2001,558.950
OpenGreater thanClose1,475.000
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in IDR. All numbers in thousands.

Summary
Total Assets27,181,763,267
Total Liabilities6,506,208,543
Total Stockholder Equity20,675,554,724
 As reported
Total Liabilities 6,506,208,543
Total Stockholder Equity+ 20,675,554,724
Total Assets = 27,181,763,267

Assets

Total Assets27,181,763,267
Total Current Assets16,316,381,205
Long-term Assets10,865,382,062
Total Current Assets
Cash And Cash Equivalents 1,276,896,798
Short-term Investments 149,197,652
Net Receivables 4,995,394,432
Inventory 7,190,098,842
Other Current Assets 74,055,510
Total Current Assets  (as reported)16,316,381,205
Total Current Assets  (calculated)13,685,643,233
+/- 2,630,737,972
Long-term Assets
Property Plant Equipment 8,456,456,628
Goodwill 479,347,420
Intangible Assets 1,156,476,987
Other Assets 236,446,667
Long-term Assets  (as reported)10,865,382,062
Long-term Assets  (calculated)10,328,727,701
+/- 536,654,361

Liabilities & Shareholders' Equity

Total Current Liabilities4,178,640,602
Long-term Liabilities629,386,753
Total Stockholder Equity20,675,554,724
Total Current Liabilities
Short-term Debt 737,390,046
Short Long Term Debt 865,374,505
Accounts payable 1,900,735,126
Total Current Liabilities  (as reported)4,178,640,602
Total Current Liabilities  (calculated)3,503,499,677
+/- 675,140,925
Long-term Liabilities
Long term Debt Total 200,247,921
Long term Debt 190,865,112
Capital Lease Obligations 29,824,404
Long-term Liabilities  (as reported)629,386,753
Long-term Liabilities  (calculated)420,937,437
+/- 208,449,316
Total Stockholder Equity
Retained Earnings 20,804,950,000
Capital Surplus -34,118,674
Total Stockholder Equity (as reported)20,675,554,724
Total Stockholder Equity (calculated)20,770,831,327
+/- 95,276,602
Other
Capital Stock468,751,221
Cash And Equivalents1,541,442,330
Cash and Short Term Investments 2,967,536,779
Common Stock Shares Outstanding 46,255,641
Liabilities and Stockholders Equity 27,181,763,267
Net Invested Capital 21,731,794,342
Net Working Capital 12,137,740,603
Property Plant and Equipment Gross 14,107,354,466



Balance Sheet

Currency in IDR. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-06-302002-12-312002-06-302001-12-312001-06-30
> Total Assets 
1,944,788,000
1,877,316,000
2,077,523,000
2,015,537,544
2,266,091,000
2,448,390,203
2,574,785,300
2,781,187,816
3,062,276,501
3,016,864,059
3,336,392,866
3,626,669,423
3,772,954,628
4,728,368,510
4,727,232,922
5,262,953,669
4,883,383,250
4,624,619,205
5,025,473,577
5,202,946,390
5,434,110,753
5,138,212,507
5,452,935,354
5,679,955,118
5,767,835,346
5,703,832,412
6,118,610,548
6,671,261,047
6,264,537,851
6,482,446,670
6,623,188,538
6,876,153,112
6,678,574,696
7,032,496,663
7,517,370,313
7,894,851,261
7,513,703,907
8,274,554,113
8,696,130,987
9,141,115,981
8,745,245,327
9,417,957,181
9,845,455,246
10,868,696,854
10,451,743,692
11,315,061,275
11,622,560,401
12,323,759,632
12,017,762,709
12,425,032,368
13,019,851,457
12,723,559,627
13,259,344,411
13,696,417,381
14,434,431,483
14,228,612,661
14,688,501,466
15,226,009,211
15,916,481,576
16,437,500,116
16,224,398,948
16,616,239,416
17,306,798,207
17,892,981,268
17,530,868,911
18,146,206,145
19,177,851,015
18,813,050,577
19,593,943,644
20,264,726,863
22,132,154,300
22,091,102,524
22,450,538,570
22,564,300,317
23,931,375,140
23,407,459,737
24,266,776,391
25,666,635,156
26,861,580,834
25,263,347,747
26,187,153,771
27,241,313,026
28,239,682,359
27,419,566,534
27,181,763,267
27,181,763,26727,419,566,53428,239,682,35927,241,313,02626,187,153,77125,263,347,74726,861,580,83425,666,635,15624,266,776,39123,407,459,73723,931,375,14022,564,300,31722,450,538,57022,091,102,52422,132,154,30020,264,726,86319,593,943,64418,813,050,57719,177,851,01518,146,206,14517,530,868,91117,892,981,26817,306,798,20716,616,239,41616,224,398,94816,437,500,11615,916,481,57615,226,009,21114,688,501,46614,228,612,66114,434,431,48313,696,417,38113,259,344,41112,723,559,62713,019,851,45712,425,032,36812,017,762,70912,323,759,63211,622,560,40111,315,061,27510,451,743,69210,868,696,8549,845,455,2469,417,957,1818,745,245,3279,141,115,9818,696,130,9878,274,554,1137,513,703,9077,894,851,2617,517,370,3137,032,496,6636,678,574,6966,876,153,1126,623,188,5386,482,446,6706,264,537,8516,671,261,0476,118,610,5485,703,832,4125,767,835,3465,679,955,1185,452,935,3545,138,212,5075,434,110,7535,202,946,3905,025,473,5774,624,619,2054,883,383,2505,262,953,6694,727,232,9224,728,368,5103,772,954,6283,626,669,4233,336,392,8663,016,864,0593,062,276,5012,781,187,8162,574,785,3002,448,390,2032,266,091,0002,015,537,5442,077,523,0001,877,316,0001,944,788,000
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,322,941,876
10,648,288,387
11,326,325,660
10,661,178,989
11,084,871,212
11,222,490,978
12,672,173,478
12,607,408,568
12,887,113,860
13,075,331,881
14,091,243,420
13,624,909,478
14,423,154,322
15,712,209,508
16,878,091,073
15,296,866,906
16,149,431,091
16,710,229,570
17,568,017,775
16,658,840,370
16,316,381,205
16,316,381,20516,658,840,37017,568,017,77516,710,229,57016,149,431,09115,296,866,90616,878,091,07315,712,209,50814,423,154,32213,624,909,47814,091,243,42013,075,331,88112,887,113,86012,607,408,56812,672,173,47811,222,490,97811,084,871,21210,661,178,98911,326,325,66010,648,288,38710,322,941,8760000000000000000000000000000000000000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,528,943,903
3,153,327,557
3,201,308,324
2,478,404,129
1,649,709,766
3,040,487,104
3,926,684,026
4,011,875,677
4,401,391,559
2,883,075,063
2,959,144,513
1,916,297,166
2,845,468,621
3,323,690,210
2,987,503,551
4,133,490,287
2,556,486,671
1,634,556,836
1,499,352,913
1,114,053,434
1,276,896,798
1,276,896,7981,114,053,4341,499,352,9131,634,556,8362,556,486,6714,133,490,2872,987,503,5513,323,690,2102,845,468,6211,916,297,1662,959,144,5132,883,075,0634,401,391,5594,011,875,6773,926,684,0263,040,487,1041,649,709,7662,478,404,1293,201,308,3243,153,327,5572,528,943,9030000000000000000000000000000000000000000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
175,154,489
178,719,216
183,827,876
187,560,562
191,898,606
195,618,536
199,353,914
181,664,048
185,595,253
188,316,348
190,243,852
190,716,977
185,191,852
258,923,290
260,104,322
214,274,338
168,177,084
145,306,837
145,654,789
147,611,627
149,197,652
149,197,652147,611,627145,654,789145,306,837168,177,084214,274,338260,104,322258,923,290185,191,852190,716,977190,243,852188,316,348185,595,253181,664,048199,353,914195,618,536191,898,606187,560,562183,827,876178,719,216175,154,4890000000000000000000000000000000000000000000000000000000000000000
       Net Receivables 
419,741,000
423,918,000
551,921,000
466,558,873
576,683,000
547,151,424
694,973,913
683,797,419
726,707,212
616,858,629
785,473,303
914,718,185
891,377,334
632,313,904
694,236,500
688,000,017
789,950,379
798,032,428
858,871,508
779,563,451
919,726,317
943,160,675
920,792,605
1,008,393,790
1,048,911,611
1,013,681,172
1,050,488,487
1,163,253,936
1,316,690,481
1,326,418,432
1,272,670,244
1,504,740,589
1,405,792,645
1,363,957,103
1,374,228,441
1,586,781,380
1,600,224,386
1,635,311,257
1,747,951,651
1,709,808,116
1,832,803,942
1,938,155,599
1,993,770,196
2,203,675,827
2,292,903,590
2,273,378,788
2,428,965,173
2,455,619,602
2,416,777,358
2,464,901,530
2,510,299,193
2,642,602,730
2,728,998,563
2,434,081,759
2,671,849,200
2,660,195,600
2,734,275,022
2,725,807,581
3,005,851,159
3,154,233,702
3,298,100,784
2,967,693,268
2,999,317,415
3,603,338,686
3,599,203,677
3,373,569,270
3,540,431,151
3,664,219,406
3,789,897,516
3,697,660,122
3,961,641,104
3,617,297,231
3,607,724,999
3,594,926,678
3,857,428,431
3,962,719,252
3,668,397,846
3,545,142,656
3,820,562,920
4,171,544,078
4,459,572,526
4,613,623,001
5,247,147,073
5,438,365,196
4,995,394,432
4,995,394,4325,438,365,1965,247,147,0734,613,623,0014,459,572,5264,171,544,0783,820,562,9203,545,142,6563,668,397,8463,962,719,2523,857,428,4313,594,926,6783,607,724,9993,617,297,2313,961,641,1043,697,660,1223,789,897,5163,664,219,4063,540,431,1513,373,569,2703,599,203,6773,603,338,6862,999,317,4152,967,693,2683,298,100,7843,154,233,7023,005,851,1592,725,807,5812,734,275,0222,660,195,6002,671,849,2002,434,081,7592,728,998,5632,642,602,7302,510,299,1932,464,901,5302,416,777,3582,455,619,6022,428,965,1732,273,378,7882,292,903,5902,203,675,8271,993,770,1961,938,155,5991,832,803,9421,709,808,1161,747,951,6511,635,311,2571,600,224,3861,586,781,3801,374,228,4411,363,957,1031,405,792,6451,504,740,5891,272,670,2441,326,418,4321,316,690,4811,163,253,9361,050,488,4871,013,681,1721,048,911,6111,008,393,790920,792,605943,160,675919,726,317779,563,451858,871,508798,032,428789,950,379688,000,017694,236,500632,313,904891,377,334914,718,185785,473,303616,858,629726,707,212683,797,419694,973,913547,151,424576,683,000466,558,873551,921,000423,918,000419,741,000
       Other Current Assets 
0
20,059,000
0
24,544,155
62,562,000
19,198,005
65,364,765
0
659,954,437
0
822,318,337
863,052,871
713,442,009
0
194,202,758
274,529,676
319,479,581
117,436,051
232,743,653
316,587,643
385,488,077
97,599,681
416,223,656
529,880,570
435,643,186
101,703,568
278,148,115
355,314,959
462,246,095
188,831,229
339,253,521
272,119,184
237,967,735
209,571,257
246,197,092
260,512,033
257,996,994
247,697,888
280,811,032
294,243,930
320,474,797
289,221,175
398,859,775
537,787,698
554,720,097
556,242,245
557,080,819
557,222,288
604,317,308
471,360,489
534,781,758
488,510,658
485,210,101
436,887,578
547,699,607
616,356,146
608,191,585
427,409,912
610,482,246
641,797,549
525,631,585
547,559,520
634,752,161
605,667,261
465,570,428
405,867,031
49,122,608
53,145,255
59,192,077
318,138,653
528,300,677
384,492,247
327,835,193
304,003,819
374,642,124
360,380,057
391,552,659
468,944,753
58,191,792
553,069,274
560,999,730
656,890,502
704,633,555
731,200,665
74,055,510
74,055,510731,200,665704,633,555656,890,502560,999,730553,069,27458,191,792468,944,753391,552,659360,380,057374,642,124304,003,819327,835,193384,492,247528,300,677318,138,65359,192,07753,145,25549,122,608405,867,031465,570,428605,667,261634,752,161547,559,520525,631,585641,797,549610,482,246427,409,912608,191,585616,356,146547,699,607436,887,578485,210,101488,510,658534,781,758471,360,489604,317,308557,222,288557,080,819556,242,245554,720,097537,787,698398,859,775289,221,175320,474,797294,243,930280,811,032247,697,888257,996,994260,512,033246,197,092209,571,257237,967,735272,119,184339,253,521188,831,229462,246,095355,314,959278,148,115101,703,568435,643,186529,880,570416,223,65697,599,681385,488,077316,587,643232,743,653117,436,051319,479,581274,529,676194,202,7580713,442,009863,052,871822,318,3370659,954,437065,364,76519,198,00562,562,00024,544,155020,059,0000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,851,525,355
8,151,871,588
8,509,072,432
9,042,235,884
9,459,980,822
9,483,693,956
9,563,424,710
9,488,968,437
9,840,131,719
9,782,550,259
9,843,622,069
9,954,425,649
9,983,489,760
9,966,480,840
10,037,722,680
10,531,083,456
10,671,664,584
10,760,726,164
10,865,382,062
10,865,382,06210,760,726,16410,671,664,58410,531,083,45610,037,722,6809,966,480,8409,983,489,7609,954,425,6499,843,622,0699,782,550,2599,840,131,7199,488,968,4379,563,424,7109,483,693,9569,459,980,8229,042,235,8848,509,072,4328,151,871,5887,851,525,355000000000000000000000000000000000000000000000000000000000000000000
       Property Plant Equipment 
428,605,000
444,305,000
447,350,000
493,813,551
480,308,000
520,374,422
524,482,430
523,252,629
531,939,134
557,746,594
572,518,114
623,728,104
683,893,614
859,117,129
936,675,379
985,660,223
1,019,039,567
815,420,687
1,031,261,863
954,617,808
974,387,372
983,020,082
1,003,943,097
1,018,547,210
1,048,400,720
1,097,030,469
1,097,203,022
1,108,718,052
1,111,867,588
1,398,127,877
1,415,892,690
1,488,562,707
1,512,770,486
1,605,266,031
1,625,766,960
1,669,633,743
1,701,959,330
1,860,288,484
1,966,530,426
2,110,326,521
2,170,297,702
2,254,763,273
2,367,638,129
2,611,517,729
2,734,624,182
2,925,546,783
2,993,241,847
3,105,018,638
3,253,620,387
3,404,457,131
3,503,125,548
3,600,486,287
3,802,024,577
3,938,494,052
3,989,100,382
4,128,376,308
4,466,621,788
4,555,756,102
4,606,437,078
4,672,297,344
4,950,644,822
5,342,659,713
5,406,027,092
5,533,818,604
5,930,201,157
6,252,801,150
6,668,453,841
6,954,262,621
7,326,230,151
7,666,314,693
8,084,999,061
8,279,933,749
8,351,114,114
8,310,144,410
8,269,241,658
8,173,338,171
8,109,927,307
8,101,932,953
8,332,259,559
8,029,370,210
8,246,199,016
8,346,611,361
8,352,656,729
8,366,601,552
8,456,456,628
8,456,456,6288,366,601,5528,352,656,7298,346,611,3618,246,199,0168,029,370,2108,332,259,5598,101,932,9538,109,927,3078,173,338,1718,269,241,6588,310,144,4108,351,114,1148,279,933,7498,084,999,0617,666,314,6937,326,230,1516,954,262,6216,668,453,8416,252,801,1505,930,201,1575,533,818,6045,406,027,0925,342,659,7134,950,644,8224,672,297,3444,606,437,0784,555,756,1024,466,621,7884,128,376,3083,989,100,3823,938,494,0523,802,024,5773,600,486,2873,503,125,5483,404,457,1313,253,620,3873,105,018,6382,993,241,8472,925,546,7832,734,624,1822,611,517,7292,367,638,1292,254,763,2732,170,297,7022,110,326,5211,966,530,4261,860,288,4841,701,959,3301,669,633,7431,625,766,9601,605,266,0311,512,770,4861,488,562,7071,415,892,6901,398,127,8771,111,867,5881,108,718,0521,097,203,0221,097,030,4691,048,400,7201,018,547,2101,003,943,097983,020,082974,387,372954,617,8081,031,261,863815,420,6871,019,039,567985,660,223936,675,379859,117,129683,893,614623,728,104572,518,114557,746,594531,939,134523,252,629524,482,430520,374,422480,308,000493,813,551447,350,000444,305,000428,605,000
       Goodwill 
0
44,086,000
0
37,712,015
57,364,000
34,540,865
0
0
0
30,730,804
0
0
0
36,121,365
35,168,850
35,229,753
33,901,046
32,092,703
31,508,985
30,925,268
30,341,551
28,064,040
0
0
0
24,264,604
23,257,438
22,250,273
227,925,065
210,683,228
207,770,162
204,594,664
201,419,166
195,217,374
195,217,374
195,217,374
195,217,374
195,217,374
195,217,374
195,217,374
298,580,258
298,588,100
298,588,100
294,418,921
294,418,921
294,015,103
294,015,103
294,015,103
293,411,778
293,279,778
293,279,778
293,279,778
293,279,778
293,279,778
293,279,778
293,279,778
293,279,778
293,279,778
293,279,778
293,279,778
293,279,778
293,279,778
293,279,778
293,279,778
293,279,778
293,279,778
293,279,778
293,279,778
293,279,778
293,279,778
293,279,778
293,279,778
293,279,778
195,225,854
209,683,528
209,683,528
209,683,528
209,683,528
209,683,528
209,683,528
209,683,528
479,347,420
479,347,420
479,347,420
479,347,420
479,347,420479,347,420479,347,420479,347,420209,683,528209,683,528209,683,528209,683,528209,683,528209,683,528209,683,528195,225,854293,279,778293,279,778293,279,778293,279,778293,279,778293,279,778293,279,778293,279,778293,279,778293,279,778293,279,778293,279,778293,279,778293,279,778293,279,778293,279,778293,279,778293,279,778293,279,778293,279,778293,279,778293,279,778293,279,778293,279,778293,411,778294,015,103294,015,103294,015,103294,418,921294,418,921298,588,100298,588,100298,580,258195,217,374195,217,374195,217,374195,217,374195,217,374195,217,374195,217,374201,419,166204,594,664207,770,162210,683,228227,925,06522,250,27323,257,43824,264,60400028,064,04030,341,55130,925,26831,508,98532,092,70333,901,04635,229,75335,168,85036,121,36500030,730,80400034,540,86557,364,00037,712,015044,086,0000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
86,089,639
86,106,431
85,216,745
89,513,905
87,609,898
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000087,609,89889,513,90585,216,74586,106,43186,089,6390000000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
71,529,000
0
66,419,301
63,678,000
61,330,215
60,051,767
58,778,635
57,479,792
55,602,217
54,337,898
53,073,583
51,809,265
63,615,572
61,958,576
61,453,896
59,063,502
270,589,943
61,852,306
290,517,676
290,100,090
292,150,844
296,877,024
300,163,091
299,704,818
312,723,407
310,376,963
311,673,765
529,899,360
261,359,311
256,065,025
252,808,140
246,915,537
237,557,876
235,156,262
232,846,677
230,414,539
233,007,451
230,898,966
230,323,882
343,269,108
341,173,421
338,654,445
338,167,001
340,120,923
385,267,577
410,623,100
405,906,902
411,014,176
421,707,972
435,341,856
422,068,406
415,202,431
415,279,755
425,710,365
435,425,989
430,717,461
400,206,315
406,182,962
395,133,495
402,890,538
419,572,829
415,996,645
452,847,192
120,965,934
140,160,920
173,130,867
188,835,228
203,292,568
399,173,412
385,145,572
406,483,430
419,718,267
464,791,872
830,672,207
854,720,900
865,256,238
923,047,655
932,917,991
981,444,022
974,465,209
1,026,046,475
1,032,792,156
1,137,391,478
1,156,476,987
1,156,476,9871,137,391,4781,032,792,1561,026,046,475974,465,209981,444,022932,917,991923,047,655865,256,238854,720,900830,672,207464,791,872419,718,267406,483,430385,145,572399,173,412203,292,568188,835,228173,130,867140,160,920120,965,934452,847,192415,996,645419,572,829402,890,538395,133,495406,182,962400,206,315430,717,461435,425,989425,710,365415,279,755415,202,431422,068,406435,341,856421,707,972411,014,176405,906,902410,623,100385,267,577340,120,923338,167,001338,654,445341,173,421343,269,108230,323,882230,898,966233,007,451230,414,539232,846,677235,156,262237,557,876246,915,537252,808,140256,065,025261,359,311529,899,360311,673,765310,376,963312,723,407299,704,818300,163,091296,877,024292,150,844290,100,090290,517,67661,852,306270,589,94359,063,50261,453,89661,958,57663,615,57251,809,26553,073,58354,337,89855,602,21757,479,79258,778,63560,051,76761,330,21563,678,00066,419,301071,529,0000
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18,125,905
21,495,066
32,449,980
33,945,038
33,588,526
26,864,495
17,060,645
19,071,674
18,721,385
20,001,172
36,127,225
16,965,003
11,601,248
17,227,605
326,136,841
14,008,249
10,084,941
13,993,714
12,902,564
12,902,56413,993,71410,084,94114,008,249326,136,84117,227,60511,601,24816,965,00336,127,22520,001,17218,721,38519,071,67417,060,64526,864,49533,588,52633,945,03832,449,98021,495,06618,125,905000000000000000000000000000000000000000000000000000000000000000000
> Total Liabilities 
1,633,385,000
1,531,342,000
1,455,011,000
1,364,124,530
1,395,133,000
1,424,895,577
1,416,522,020
1,537,620,174
1,662,159,076
1,537,379,862
1,585,119,999
1,714,479,847
1,723,995,128
1,822,023,166
1,625,065,195
1,941,411,120
1,410,692,421
1,080,565,632
1,244,727,445
1,365,779,626
1,447,589,831
1,121,539,026
1,392,511,377
1,542,202,378
1,605,158,725
1,359,296,592
1,625,459,085
1,999,890,274
1,809,569,817
1,691,774,827
1,554,359,925
1,733,653,222
1,320,404,818
1,260,579,634
1,362,130,700
2,049,757,116
1,440,812,922
1,758,619,054
1,753,018,065
2,710,056,999
1,874,940,253
2,046,313,566
1,999,683,775
3,421,591,223
2,531,007,897
2,815,103,309
2,629,701,283
3,600,724,165
2,795,654,154
2,607,556,689
2,648,911,209
2,711,971,171
2,770,785,539
2,758,131,396
2,914,178,902
2,994,581,917
2,875,016,259
2,762,162,070
2,837,164,154
3,761,971,845
2,960,936,481
2,722,207,634
2,798,766,579
3,921,410,965
2,952,878,831
2,851,611,349
3,320,263,540
3,516,192,524
4,271,074,695
3,559,144,387
4,875,822,011
4,910,431,691
4,547,942,043
5,158,767,388
5,616,640,992
5,516,449,233
5,697,470,390
6,087,108,914
6,619,831,638
4,533,532,673
6,716,374,916
6,856,095,054
7,039,337,845
7,310,211,976
6,506,208,543
6,506,208,5437,310,211,9767,039,337,8456,856,095,0546,716,374,9164,533,532,6736,619,831,6386,087,108,9145,697,470,3905,516,449,2335,616,640,9925,158,767,3884,547,942,0434,910,431,6914,875,822,0113,559,144,3874,271,074,6953,516,192,5243,320,263,5402,851,611,3492,952,878,8313,921,410,9652,798,766,5792,722,207,6342,960,936,4813,761,971,8452,837,164,1542,762,162,0702,875,016,2592,994,581,9172,914,178,9022,758,131,3962,770,785,5392,711,971,1712,648,911,2092,607,556,6892,795,654,1543,600,724,1652,629,701,2832,815,103,3092,531,007,8973,421,591,2231,999,683,7752,046,313,5661,874,940,2532,710,056,9991,753,018,0651,758,619,0541,440,812,9222,049,757,1161,362,130,7001,260,579,6341,320,404,8181,733,653,2221,554,359,9251,691,774,8271,809,569,8171,999,890,2741,625,459,0851,359,296,5921,605,158,7251,542,202,3781,392,511,3771,121,539,0261,447,589,8311,365,779,6261,244,727,4451,080,565,6321,410,692,4211,941,411,1201,625,065,1951,822,023,1661,723,995,1281,714,479,8471,585,119,9991,537,379,8621,662,159,0761,537,620,1741,416,522,0201,424,895,5771,395,133,0001,364,124,5301,455,011,0001,531,342,0001,633,385,000
   > Total Current Liabilities 
514,573,000
500,475,000
472,438,000
1,133,666,099
1,144,583,000
1,161,321,161
1,176,389,309
1,303,548,324
1,428,051,418
782,589,561
834,632,568
927,559,518
900,462,084
903,515,824
775,523,476
852,457,874
999,296,366
658,759,611
790,391,163
899,856,232
1,088,188,213
754,629,114
1,026,783,573
1,181,912,548
1,506,928,373
1,250,371,831
1,517,230,167
1,887,029,877
1,695,369,263
1,574,137,416
1,436,771,688
1,615,884,207
1,215,566,512
1,146,489,094
1,248,441,931
1,935,642,040
1,325,953,746
1,630,588,529
1,621,568,221
2,576,078,966
1,738,284,006
1,891,617,854
1,845,248,674
3,262,993,017
2,367,735,950
2,640,590,024
2,464,523,248
3,437,839,137
2,610,289,665
2,385,920,173
2,403,854,559
2,437,282,889
2,466,068,664
2,365,880,491
2,510,017,563
2,579,824,771
2,461,491,094
2,317,161,787
2,394,356,947
3,303,123,584
2,491,484,132
2,227,336,012
2,301,275,637
3,382,316,838
2,427,567,833
2,286,167,472
2,652,092,866
2,658,377,796
2,551,863,789
2,577,108,806
3,848,869,598
3,858,586,635
3,362,011,465
3,176,726,212
3,507,575,318
3,124,616,229
3,325,096,534
3,534,656,089
4,040,387,563
3,747,342,453
4,253,260,301
4,431,038,460
4,611,540,126
4,979,643,329
4,178,640,602
4,178,640,6024,979,643,3294,611,540,1264,431,038,4604,253,260,3013,747,342,4534,040,387,5633,534,656,0893,325,096,5343,124,616,2293,507,575,3183,176,726,2123,362,011,4653,858,586,6353,848,869,5982,577,108,8062,551,863,7892,658,377,7962,652,092,8662,286,167,4722,427,567,8333,382,316,8382,301,275,6372,227,336,0122,491,484,1323,303,123,5842,394,356,9472,317,161,7872,461,491,0942,579,824,7712,510,017,5632,365,880,4912,466,068,6642,437,282,8892,403,854,5592,385,920,1732,610,289,6653,437,839,1372,464,523,2482,640,590,0242,367,735,9503,262,993,0171,845,248,6741,891,617,8541,738,284,0062,576,078,9661,621,568,2211,630,588,5291,325,953,7461,935,642,0401,248,441,9311,146,489,0941,215,566,5121,615,884,2071,436,771,6881,574,137,4161,695,369,2631,887,029,8771,517,230,1671,250,371,8311,506,928,3731,181,912,5481,026,783,573754,629,1141,088,188,213899,856,232790,391,163658,759,611999,296,366852,457,874775,523,476903,515,824900,462,084927,559,518834,632,568782,589,5611,428,051,4181,303,548,3241,176,389,3091,161,321,1611,144,583,0001,133,666,099472,438,000500,475,000514,573,000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
22,499,631
27,102,573
147,560,549
203,260,527
109,434,675
169,062,533
447,661,579
753,082,180
406,383,317
220,500,000
48,000,000
126,000,000
60,000,000
0
152,000,000
110,000,000
595,000,000
705,600,000
465,400,000
1,458,200,000
737,390,046
737,390,0461,458,200,000465,400,000705,600,000595,000,000110,000,000152,000,000060,000,000126,000,00048,000,000220,500,000406,383,317753,082,180447,661,579169,062,533109,434,675203,260,527147,560,54927,102,57322,499,6310000000000000000000000000000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
22,499,631
27,102,573
147,560,549
203,260,527
138,615,927
169,062,533
515,227,596
961,542,719
589,202,664
344,343,143
145,367,111
160,891,933
81,442,298
69,999,978
208,458,308
156,483,804
626,542,799
829,302,294
566,253,209
1,585,474,959
865,374,505
865,374,5051,585,474,959566,253,209829,302,294626,542,799156,483,804208,458,30869,999,97881,442,298160,891,933145,367,111344,343,143589,202,664961,542,719515,227,596169,062,533138,615,927203,260,527147,560,54927,102,57322,499,6310000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
0
101,289,000
0
99,391,211
108,827,000
103,118,924
148,999,656
181,792,840
187,997,231
151,360,549
196,085,878
213,143,159
206,768,483
306,454,180
265,835,017
292,372,261
353,737,759
344,374,324
380,533,240
346,067,792
408,095,163
328,290,780
525,606,216
515,692,805
538,712,529
305,567,570
422,849,601
535,294,069
475,006,616
481,511,454
489,435,121
586,401,835
429,282,090
488,240,634
518,734,407
624,173,006
681,252,384
850,398,382
788,661,717
868,710,908
904,531,831
808,864,742
938,944,523
1,103,271,422
1,205,067,925
1,151,654,580
1,121,630,562
1,191,076,919
1,229,927,238
1,133,092,820
1,088,782,998
1,056,659,532
1,131,222,609
1,068,665,524
1,135,461,006
1,151,040,259
1,051,032,650
1,127,307,240
1,088,550,367
1,058,057,127
1,059,944,455
1,108,551,385
1,078,496,322
919,308,351
1,186,062,513
1,289,897,769
1,242,251,439
1,219,015,987
1,272,604,706
1,215,860,422
1,405,491,530
1,349,278,910
1,124,598,987
1,240,385,598
1,641,334,570
1,374,346,315
1,411,315,051
1,667,595,791
1,943,821,427
1,903,687,912
1,967,161,077
1,996,614,608
2,460,574,222
2,083,742,786
1,900,735,126
1,900,735,1262,083,742,7862,460,574,2221,996,614,6081,967,161,0771,903,687,9121,943,821,4271,667,595,7911,411,315,0511,374,346,3151,641,334,5701,240,385,5981,124,598,9871,349,278,9101,405,491,5301,215,860,4221,272,604,7061,219,015,9871,242,251,4391,289,897,7691,186,062,513919,308,3511,078,496,3221,108,551,3851,059,944,4551,058,057,1271,088,550,3671,127,307,2401,051,032,6501,151,040,2591,135,461,0061,068,665,5241,131,222,6091,056,659,5321,088,782,9981,133,092,8201,229,927,2381,191,076,9191,121,630,5621,151,654,5801,205,067,9251,103,271,422938,944,523808,864,742904,531,831868,710,908788,661,717850,398,382681,252,384624,173,006518,734,407488,240,634429,282,090586,401,835489,435,121481,511,454475,006,616535,294,069422,849,601305,567,570538,712,529515,692,805525,606,216328,290,780408,095,163346,067,792380,533,240344,374,324353,737,759292,372,261265,835,017306,454,180206,768,483213,143,159196,085,878151,360,549187,997,231181,792,840148,999,656103,118,924108,827,00099,391,2110101,289,0000
       Other Current Liabilities 
0
130,441,000
0
145,007,728
289,130,000
284,156,726
275,060,859
313,497,824
439,582,455
354,990,788
349,208,118
458,051,896
465,690,753
426,334,849
415,912,655
478,489,031
598,642,580
276,072,721
360,185,438
491,386,705
631,516,263
380,185,930
454,435,295
608,854,586
588,897,765
539,791,314
688,135,845
750,780,398
914,131,329
752,993,595
782,717,969
871,676,243
618,935,252
633,649,816
532,471,790
1,171,701,427
528,770,181
639,848,211
705,068,590
1,643,053,102
718,058,074
878,206,920
692,309,598
1,744,977,162
760,514,843
905,020,145
780,229,157
1,647,426,139
871,202,378
1,000,918,251
1,132,932,555
1,036,412,952
1,035,170,118
1,029,237,605
1,091,730,420
1,211,262,439
1,245,737,296
1,041,161,931
1,116,367,869
2,056,135,990
1,089,319,816
945,395,721
1,029,900,504
2,295,979,344
573,749,887
560,236,764
840,707,505
786,829,861
626,393,820
684,107,305
1,236,814,173
894,619,697
907,271,613
1,034,907,890
1,080,512,888
988,095,422
1,052,347,085
1,038,436,604
0
811,901,320
755,484,279
961,791,105
877,186,411
662,555,623
0
0662,555,623877,186,411961,791,105755,484,279811,901,32001,038,436,6041,052,347,085988,095,4221,080,512,8881,034,907,890907,271,613894,619,6971,236,814,173684,107,305626,393,820786,829,861840,707,505560,236,764573,749,8872,295,979,3441,029,900,504945,395,7211,089,319,8162,056,135,9901,116,367,8691,041,161,9311,245,737,2961,211,262,4391,091,730,4201,029,237,6051,035,170,1181,036,412,9521,132,932,5551,000,918,251871,202,3781,647,426,139780,229,157905,020,145760,514,8431,744,977,162692,309,598878,206,920718,058,0741,643,053,102705,068,590639,848,211528,770,1811,171,701,427532,471,790633,649,816618,935,252871,676,243782,717,969752,993,595914,131,329750,780,398688,135,845539,791,314588,897,765608,854,586454,435,295380,185,930631,516,263491,386,705360,185,438276,072,721598,642,580478,489,031415,912,655426,334,849465,690,753458,051,896349,208,118354,990,788439,582,455313,497,824275,060,859284,156,726289,130,000145,007,7280130,441,0000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
668,170,675
857,814,728
906,179,068
982,035,581
1,026,952,413
1,051,845,056
1,185,930,579
1,111,491,962
968,380,678
966,049,000
949,938,533
866,101,274
875,213,266
786,190,220
785,073,935
712,946,364
706,949,284
663,294,365
629,386,753
629,386,753663,294,365706,949,284712,946,364785,073,935786,190,220875,213,266866,101,274949,938,533966,049,000968,380,6781,111,491,9621,185,930,5791,051,845,0561,026,952,413982,035,581906,179,068857,814,728668,170,675000000000000000000000000000000000000000000000000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
594,193,179
647,688,345
689,433,821
711,300,946
834,908,488
788,551,546
640,227,605
628,236,430
614,953,970
532,509,477
526,908,930
439,904,249
430,752,842
311,898,813
299,310,339
237,911,335
200,247,921
200,247,921237,911,335299,310,339311,898,813430,752,842439,904,249526,908,930532,509,477614,953,970628,236,430640,227,605788,551,546834,908,488711,300,946689,433,821647,688,345594,193,17900000000000000000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
7,335,000
0
15,777,933
23,491,000
24,295,980
22,376,306
24,619,333
24,278,940
36,494,115
31,117,759
35,761,027
35,117,448
57,503,990
64,373,592
63,541,312
54,844,682
71,107,653
70,404,456
71,610,642
72,375,244
88,944,720
89,243,211
89,352,305
86,895,240
100,723,187
99,053,104
103,534,814
105,003,319
108,265,139
108,384,811
108,663,118
99,250,802
105,706,560
105,574,130
106,074,130
106,879,649
117,826,727
121,296,615
123,920,503
126,641,150
143,685,010
143,480,314
147,665,860
152,339,601
162,581,805
153,246,555
150,953,547
154,524,973
164,437,997
168,041,919
174,923,030
180,063,132
254,715,639
257,619,033
260,463,507
267,722,755
310,001,728
314,067,107
315,947,023
322,388,898
348,632,009
352,265,896
355,956,415
359,791,037
305,442,034
311,409,064
316,353,764
311,985,889
334,347,236
337,518,592
340,544,110
351,022,091
322,940,415
328,153,072
337,812,570
334,984,563
333,591,797
0
346,285,971
354,321,093
0
0
425,383,030
0
0425,383,03000354,321,093346,285,9710333,591,797334,984,563337,812,570328,153,072322,940,415351,022,091340,544,110337,518,592334,347,236311,985,889316,353,764311,409,064305,442,034359,791,037355,956,415352,265,896348,632,009322,388,898315,947,023314,067,107310,001,728267,722,755260,463,507257,619,033254,715,639180,063,132174,923,030168,041,919164,437,997154,524,973150,953,547153,246,555162,581,805152,339,601147,665,860143,480,314143,685,010126,641,150123,920,503121,296,615117,826,727106,879,649106,074,130105,574,130105,706,56099,250,802108,663,118108,384,811108,265,139105,003,319103,534,81499,053,104100,723,18786,895,24089,352,30589,243,21188,944,72072,375,24471,610,64270,404,45671,107,65354,844,68263,541,31264,373,59257,503,99035,117,44835,761,02731,117,75936,494,11524,278,94024,619,33322,376,30624,295,98023,491,00015,777,93307,335,0000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
15,423,099
4,386,070
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,601,101
0
0
005,601,10100000000000000004,386,07015,423,0990000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
182,357,000
220,774,000
470,721,000
489,918,227
679,105,000
828,957,856
954,680,047
1,025,194,776
1,157,127,705
1,219,193,365
1,378,720,174
1,511,942,685
1,625,657,248
2,389,006,140
2,572,377,512
2,769,044,905
2,907,225,706
2,994,816,752
3,203,735,862
3,257,234,443
3,369,437,334
3,386,861,941
3,396,088,103
3,467,661,388
3,463,127,578
3,622,399,154
3,736,314,471
3,906,120,768
3,996,446,121
4,310,437,877
4,565,718,587
4,649,763,424
4,987,514,367
5,373,784,301
5,706,070,273
5,400,223,213
5,788,853,155
6,214,818,131
6,632,772,720
6,135,875,894
6,565,580,042
7,054,054,237
7,505,411,106
7,091,429,681
7,557,489,394
8,108,241,522
8,588,278,597
8,303,878,371
8,802,312,622
9,382,023,164
9,926,108,890
9,570,053,559
10,032,044,767
10,465,122,964
11,020,803,726
10,734,478,085
11,298,407,380
11,909,264,708
12,498,721,150
12,097,711,193
12,666,145,724
13,280,807,475
13,874,492,491
13,339,534,145
13,933,810,760
14,623,457,976
15,218,855,531
14,664,889,864
15,322,868,950
15,893,126,391
16,437,431,135
16,341,562,083
17,055,114,152
17,405,532,929
18,314,734,148
17,891,010,504
18,569,306,001
19,579,526,243
20,241,749,196
19,050,285,036
19,470,778,855
20,385,217,972
21,200,344,514
20,109,354,557
20,675,554,724
20,675,554,72420,109,354,55721,200,344,51420,385,217,97219,470,778,85519,050,285,03620,241,749,19619,579,526,24318,569,306,00117,891,010,50418,314,734,14817,405,532,92917,055,114,15216,341,562,08316,437,431,13515,893,126,39115,322,868,95014,664,889,86415,218,855,53114,623,457,97613,933,810,76013,339,534,14513,874,492,49113,280,807,47512,666,145,72412,097,711,19312,498,721,15011,909,264,70811,298,407,38010,734,478,08511,020,803,72610,465,122,96410,032,044,7679,570,053,5599,926,108,8909,382,023,1648,802,312,6228,303,878,3718,588,278,5978,108,241,5227,557,489,3947,091,429,6817,505,411,1067,054,054,2376,565,580,0426,135,875,8946,632,772,7206,214,818,1315,788,853,1555,400,223,2135,706,070,2735,373,784,3014,987,514,3674,649,763,4244,565,718,5874,310,437,8773,996,446,1213,906,120,7683,736,314,4713,622,399,1543,463,127,5783,467,661,3883,396,088,1033,386,861,9413,369,437,3343,257,234,4433,203,735,8622,994,816,7522,907,225,7062,769,044,9052,572,377,5122,389,006,1401,625,657,2481,511,942,6851,378,720,1741,219,193,3651,157,127,7051,025,194,776954,680,047828,957,856679,105,000489,918,227470,721,000220,774,000182,357,000
   Common Stock
0
406,080,000
0
406,080,000
406,080,000
406,080,000
406,080,000
406,080,000
406,080,000
406,080,000
406,080,000
406,080,000
406,080,000
507,800,721
507,800,721
507,800,721
507,800,721
507,800,721
507,800,721
507,800,721
507,800,721
507,800,721
507,800,721
507,800,721
507,800,721
507,800,721
469,924,846
469,116,696
468,676,221
468,676,221
468,676,221
468,751,221
468,751,221
468,751,221
468,751,221
507,800,721
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
507,800,721
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221
468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221507,800,721468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221468,751,221507,800,721468,751,221468,751,221468,751,221468,751,221468,676,221468,676,221468,676,221469,116,696469,924,846507,800,721507,800,721507,800,721507,800,721507,800,721507,800,721507,800,721507,800,721507,800,721507,800,721507,800,721507,800,721507,800,721406,080,000406,080,000406,080,000406,080,000406,080,000406,080,000406,080,000406,080,000406,080,000406,080,0000406,080,0000
   Retained Earnings Total Equity0000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 0000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Capital Surplus -34,118,674-34,118,674-34,118,674-34,118,674-34,118,674-34,118,674-34,118,674-34,118,674-34,118,674-34,118,674-34,118,674-34,118,674-34,118,674-34,118,674-34,118,674-34,118,674-34,118,67400000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock0000000-2,063,200-2,063,200-2,063,200-2,063,200-2,063,200-2,063,200-2,063,200-2,063,2000000000000000000000000000-687,283,369-687,283,369-687,283,369-687,283,369-687,283,369-687,283,369-687,283,369-687,283,369-687,283,369-687,283,369-687,283,369-687,283,369-687,283,369-687,283,369-688,603,393-688,603,393-688,603,393-677,268,276-662,709,392-569,510,784-533,857,073-473,887,470-383,637,822-218,311,326-142,716,035-63,553,962-23,060,082000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
44,648,801
81,597,641
81,924,028
83,616,282
65,857,319
63,254,659
166,994,023
63,685,813
137,360,864
63,174,208
255,909,777
363,809,345
251,655,390
365,988,730
331,432,822
417,452,073
404,957,761
354,923,903
315,515,934
375,554,872
340,797,243
340,797,243375,554,872315,515,934354,923,903404,957,761417,452,073331,432,822365,988,730251,655,390363,809,345255,909,77763,174,208137,360,86463,685,813166,994,02363,254,65965,857,31983,616,28281,924,02881,597,64144,648,8010000000000000000000000000000000000000000000000000000000000000000



Balance Sheet

Currency in IDR. All numbers in thousands.




Cash Flow

Currency in IDR. All numbers in thousands.




Income Statement

Currency in IDR. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue30,312,738,428
Cost of Revenue-18,436,428,298
Gross Profit11,876,310,13011,876,310,130
 
Operating Income (+$)
Gross Profit11,876,310,130
Operating Expense-26,520,567,707
Operating Income3,792,170,722-14,644,257,576
 
Operating Expense (+$)
Research Development585,303,493
Selling General Administrative4,232,069,094
Selling And Marketing Expenses-
Operating Expense26,520,567,7074,817,372,587
 
Net Interest Income (+$)
Interest Income79,901,033
Interest Expense-82,117,347
Other Finance Cost-14,414,684
Net Interest Income-16,630,998
 
Pretax Income (+$)
Operating Income3,792,170,722
Net Interest Income-16,630,998
Other Non-Operating Income Expenses-
Income Before Tax (EBT)3,873,532,3833,792,170,722
EBIT - interestExpense = -82,117,347
2,961,621,388
3,043,738,735
Interest Expense82,117,347
Earnings Before Interest and Taxes (EBIT)-3,955,649,729
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax3,873,532,383
Tax Provision-884,367,959
Net Income From Continuing Ops2,989,164,4242,989,164,424
Net Income2,961,621,388
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-16,630,998
 

Technical Analysis of Kalbe
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Kalbe. The general trend of Kalbe is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Kalbe's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Kalbe Farma Tbk PT.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1,550 < 1,555 < 1,555.

The bearish price targets are: 1,405.

Tweet this
Kalbe Farma Tbk PT Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Kalbe Farma Tbk PT. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Kalbe Farma Tbk PT Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Kalbe Farma Tbk PT. The current macd is -6.43869935.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Kalbe price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Kalbe. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Kalbe price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Kalbe Farma Tbk PT Daily Moving Average Convergence/Divergence (MACD) ChartKalbe Farma Tbk PT Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Kalbe Farma Tbk PT. The current adx is 21.47.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Kalbe shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Kalbe Farma Tbk PT Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Kalbe Farma Tbk PT. The current sar is 1,438.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Kalbe Farma Tbk PT Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Kalbe Farma Tbk PT. The current rsi is 45.55. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Kalbe Farma Tbk PT Daily Relative Strength Index (RSI) ChartKalbe Farma Tbk PT Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Kalbe Farma Tbk PT. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Kalbe price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Kalbe Farma Tbk PT Daily Stochastic Oscillator ChartKalbe Farma Tbk PT Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Kalbe Farma Tbk PT. The current cci is -13.41334275.

Kalbe Farma Tbk PT Daily Commodity Channel Index (CCI) ChartKalbe Farma Tbk PT Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Kalbe Farma Tbk PT. The current cmo is -9.27759566.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Kalbe Farma Tbk PT Daily Chande Momentum Oscillator (CMO) ChartKalbe Farma Tbk PT Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Kalbe Farma Tbk PT. The current willr is -61.53846154.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Kalbe is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Kalbe Farma Tbk PT Daily Williams %R ChartKalbe Farma Tbk PT Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Kalbe Farma Tbk PT.

Kalbe Farma Tbk PT Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Kalbe Farma Tbk PT. The current atr is 37.71.

Kalbe Farma Tbk PT Daily Average True Range (ATR) ChartKalbe Farma Tbk PT Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Kalbe Farma Tbk PT. The current obv is -938,618,288.

Kalbe Farma Tbk PT Daily On-Balance Volume (OBV) ChartKalbe Farma Tbk PT Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Kalbe Farma Tbk PT. The current mfi is 26.17.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Kalbe Farma Tbk PT Daily Money Flow Index (MFI) ChartKalbe Farma Tbk PT Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Kalbe Farma Tbk PT.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-01STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-06BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-02CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-18MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-01MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-02MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-15BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-16RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-28MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-25CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Kalbe Farma Tbk PT Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Kalbe Farma Tbk PT based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.551
Ma 20Greater thanMa 501,466.000
Ma 50Greater thanMa 1001,501.100
Ma 100Greater thanMa 2001,558.950
OpenGreater thanClose1,475.000
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Kalbe with someone you think should read this too:
  • Are you bullish or bearish on Kalbe? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Kalbe? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Kalbe Farma Tbk PT

I send you an email if I find something interesting about Kalbe Farma Tbk PT.


Comments

How you think about this?

Leave a comment

Stay informed about Kalbe Farma Tbk PT.

Receive notifications about Kalbe Farma Tbk PT in your mailbox!